• Whole genome-wide profiling
• Measures tumor fraction
• Analyzes copy number variants
• Complementary approach to targeted deep sequencing panels for a broader view of the genomic landscape of tumors
*CLIA-validated assay requires two tubes of 10mL blood
Integrating whole-genome sequencing with targeted deep sequencing panels helps to provide a broader and comprehensive view of the genomic landscape in cancer. The increasing information provided by L-P WGS can be valuable for monitoring treatment response, detecting disease progression early, and identifying emergent clones associated with therapeutic resistance.
We offer pilot program grants to select biopharma and academic partners to empower translational research and clinical studies. To initiate a study, contact us via the form below.
If you have any questions or need assistance, complete this form and we will respond within 24 hours.